NeuroSense Therapeutics (NASDAQ:NRSN) CFO Buys $200,000.00 in Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CFO Or Eisenberg acquired 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the purchase, the chief financial officer directly owned 1,504,050 shares in the company, valued at $1,203,240. This represents a 19.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

NeuroSense Therapeutics Price Performance

Shares of NRSN stock traded up $0.01 during trading on Wednesday, reaching $0.71. The company had a trading volume of 228,051 shares, compared to its average volume of 174,519. The firm’s 50 day simple moving average is $0.78 and its two-hundred day simple moving average is $0.86. NeuroSense Therapeutics Ltd. has a one year low of $0.63 and a one year high of $2.52. The company has a market capitalization of $22.95 million, a PE ratio of -1.31 and a beta of 1.56.

Institutional Trading of NeuroSense Therapeutics

Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics during the 2nd quarter worth approximately $54,000. Yorkville Advisors Global LP acquired a new stake in shares of NeuroSense Therapeutics during the 4th quarter worth approximately $77,000. Finally, Squarepoint Ops LLC grew its holdings in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares in the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NRSN. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. Roth Mkm started coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.